Physidia
Olivier Anki is an experienced professional in quality and regulatory affairs, currently serving as the Director of Quality & Regulatory Affairs at PHYSIDIA since July 2021. Previously, Olivier held the position of Vice-President for Quality & Regulatory Affairs at Bioxis Pharmaceuticals and miDiagnostics, and Director of Quality and Regulatory Affairs at Teoxane Laboratories. Throughout a career spanning over two decades, Olivier has been instrumental in defining strategic imperatives for regulatory compliance and enhancing customer satisfaction across various organizations, including Physio-Control, DJO, Fenwal, Wright Medical Technology, and Covidien. Olivier's educational background includes a degree in Microelectronics from Polytech Montpellier and a Master of Engineering in Electronic Engineering from the University of Nottingham.
This person is not in any teams
Physidia
Physidia, a company founded in 2011 in Angers, France, is today known for its expertise in home dialysis. Right from the start, the company has made innovation its principal mission, helping home patients to find back their comfort and freedom on a daily basis. Thanks to the medical and para-medical expert opin¬ion, Physidia’s engineering team was able to create the S3 monitor, 100% dedicated to performance and safety. The S3 monitor is a portable machine dedicated to daily hemodialysis, simple to use, functions securely, and is discreet in appearance. Its development is based on multidisciplinary knowledge—that of our engineers, as well as health professionals and patients. Physidia, its patients and the medical community have one single ambition: Enable every single patient to be in control of his/her treatment, allowing him to live his life again by helping him to manage his home dialysis in total autonomy and safety. The treatment has to adapt to the patient’s rhythm of life and desires, not the opposite! For all employees, Physidia’s mission is a personal human adventure with the objective to be able to respond to the needs of comfort and freedom of every single patient undergoing end-stage re-nal disease (ESRD).